These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 20458041)

  • 41. Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.
    Parikh SA; Wierda WG
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10 Suppl 1(0 1):S27-33. PubMed ID: 20529805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
    Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
    J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Bello C; Veliz M; Pinilla-Ibarz J
    Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
    Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
    Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
    Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of ofatumumab in treatment of chronic lymphocytic leukemia.
    Veliz M; Pinilla-Ibarz J
    J Blood Med; 2011; 2():71-7. PubMed ID: 22287865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
    Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
    Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
    Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
    Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Obinutuzumab for chronic lymphocytic leukemia.
    Rioufol C; Salles G
    Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Enhanced Cytotoxic Effects in B-Cell Leukemia and Lymphoma Following Activation of Prostaglandin EP4 Receptor and Targeting of CD20 Antigen by Monoclonal Antibodies.
    Markovič T; Podgornik H; Avsec D; Nabergoj S; Mlinarič-Raščan I
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
    Okroj M; Eriksson I; Österborg A; Blom AM
    Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM; Byrd JC
    Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
    J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
    Da Roit F; Engelberts PJ; Taylor RP; Breij EC; Gritti G; Rambaldi A; Introna M; Parren PW; Beurskens FJ; Golay J
    Haematologica; 2015 Jan; 100(1):77-86. PubMed ID: 25344523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of ofatumumab in the treatment of B-cell malignancies.
    Soe ZN; Allsup D
    Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.